Is it safe to follow side branch IPMNs?

Area of Science:

• Gastroenterology
• Surgical Oncology
• Hepatology

Background:

• Biliary-duct intraductal papillary mucinous neoplasms (Bd-IPMN) present diagnostic and management challenges.
• Current treatment strategies for presumed Bd-IPMN often result in overtreatment and surgical intervention.
• A critical appraisal of existing literature highlights the unsatisfactory outcomes associated with current management protocols.

Purpose of the Study:

• To critically evaluate the current management of Bd-IPMN.
• To provide recommendations for optimizing patient care and reducing unnecessary surgical interventions.
• To inform clinical decision-making regarding surveillance and treatment protocols for Bd-IPMN.

Main Methods:

• Comprehensive literature review and critical appraisal of published studies on Bd-IPMN management.
• Analysis of treatment outcomes and surgical overtreatment rates in patients with presumed Bd-IPMN.
• Comparative assessment of existing and proposed management guidelines.

Main Results:

• A high rate of surgical overtreatment is observed in patients presumed to have Bd-IPMN.
• Existing guidelines effectively identify lesions suitable for conservative management (surveillance).
• Newer guidelines allowing follow-up of larger lesions (>3 cm) require cautious application, especially in younger patients.

Conclusions:

• Individualized management tailored to patient-specific factors is crucial for presumed Bd-IPMN.
• Preference for older guidelines is suggested for most patients due to their proven efficacy in identifying safely followable lesions.
• Younger patients necessitate particularly close surveillance if managed under newer guidelines allowing for larger lesion follow-up.